Human/Mouse/Rat CDC25C Antibody Summary
Ser2-Pro473
Accession # P30307
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of Human and Mouse CDC25C by Western Blot. Western blot shows lysates of HeLa human cervical epithelial carcinoma cell line, MCF-7 human breast cancer cell line, HepG2 human hepatocellular carcinoma cell line, CHP-100 human neuroblastoma cell line, and C2C12 mouse myoblast cell line. PVDF membrane was probed with 1 µg/mL of Rat Anti-Human/Mouse/Rat CDC25C Monoclonal Antibody (Catalog # MAB4459) followed by HRP-conjugated Anti-Rat IgG Secondary Antibody (Catalog # HAF005). A specific band was detected for CDC25C at approximately 50 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
View Larger
Detection of CDC25C by Western Blot Knockdown ANXA1 Induces G2/M Cell Cycle Arrest in Glioma Cells via the PI3K/Akt Signaling Pathway. A: Inhibition of ANXA1 decreases the expression of cdc25C, cyclin B1 and cdc2, whereas cyclin D1 was not altered evidently. Western blot assay analysis was performed using anti-cdc25C, anti-cyclin B1, anti-cyclin D1, anti-beta -actin and anti-cdc2 antibodies. B: The relative amounts of cdc-25C, cyclin B1, cdc2 and Cyclin D1 were quantified by a densitometric analysis (ImageJ). C: Western blot analysis of PI3K subunit p110 alpha and p85, phosphorylation and total protein levels of Akt, GSK3 beta and beta -catenin after si-ANXA1 or si-NC transfection for 48 h. D: Quantitative charts of phosphorylation and the total level of Akt, PI3K subunit p110 alpha and p85, GSK3 beta and beta -catenin. E: Inhibition of ANXA1 has no effect on the expression of p-p65NF-kappa B and up-regulates the expression of cPLA2. Western blot assay analysis was performed using anti-p-p65NF-kappa B, anti-p65NF-kappa B, anti-cPLA2 and anti-beta -actin antibodies. F: The relative amounts of p-p65NF-kappa B and cPLA2 were quantified by a densitometric analysis (ImageJ). G: ELISA analysis of nuclear NF-kappa B activity. N = 9 per group. H: cPLA2 activity in control, si-NC and si-ANXA1 U87 cells. cPLA2 activity was determined as described in Methods. These results were expressed as the mean ± SD from three independent experiments, *p < 0.05, **p < 0.01 compared with si-NC group. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33706561), licensed under a CC-BY license. Not internally tested by R&D Systems.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CDC25C
Cell Division Cycle 25C (CDC25C) is a dual serine/threonine and tyrosine phosphatase. There are four splice variants with molecular weights of 46, 47, 49, and 53 kDa. The smaller variants lack key regulatory sites and their upregulation has been observed in prostate cancer. CDC25C regulates the G2/M cell cycle transition by dephosphorylating proteins such as Chk1. Its cellular distribution is controlled by phosphorylations that enhance 14-3-3 binding, block nuclear localization, and inhibit enzymatic activity.
Product Datasheets
Citations for Human/Mouse/Rat CDC25C Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
2
Citations: Showing 1 - 2
Filter your results:
Filter by:
-
Knockdown of Annexin-A1 Inhibits Growth, Migration and Invasion of Glioma Cells by Suppressing the PI3K/Akt Signaling Pathway
Authors: Liqing Wei, Li Li, Li Liu, Ru Yu, Xing Li, Zhenzhao Luo
ASN Neuro
-
BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells.
Authors: Mani M, Carrasco DE, Zhang Y, Takada K, Gatt ME, Dutta-Simmons J, Ikeda H, Diaz-Griffero F, Pena-Cruz V, Bertagnolli M, Myeroff LL, Markowitz SD, Anderson KC, Carrasco DR
Cancer Res., 2009-09-08;69(19):7577-86.
Species: Mouse
Sample Types: Whole Tissue
Applications: IHC-Fr
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human/Mouse/Rat CDC25C Antibody
Average Rating: 4 (Based on 1 Review)
Have you used Human/Mouse/Rat CDC25C Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
